Renal denervation using carbon dioxide renal angiography in patients with uncontrolled hypertension and moderate to severe chronic kidney disease

Mohammed Awais Hameed¹,², Jonathan S. Freedman², Richard Watkin², Arul Ganeshan² and Indranil Dasgupta²,³

¹Institute of Applied Health Research, University of Birmingham, Birmingham, UK, ²Heart of England NHS Foundation Trust, Birmingham, UK and ³Aston Medical School, Aston University, Birmingham, UK

Correspondence and offprint requests to: Indranil Dasgupta; E-mail: indranil.dasgupta@heartofengland.nhs.uk

Abstract

Background: Chronic kidney disease (CKD) is the most common cause of secondary hypertension. More than half of the patients have uncontrolled hypertension (>140/90 mmHg on three or more antihypertensive agents at optimum doses). Renal sympathetic denervation (RSDN) has been shown to reduce blood pressure (BP) in patients with resistant hypertension. Although patients with CKD have high sympathetic drive, all major clinical trials have excluded patients with estimated glomerular filtration rates (eGFRs) <45 mL/min/1.73m² for risk of contrast-induced nephropathy.

Methods: In this pilot study, carbon dioxide (CO₂) was used as the sole contrast agent to carry out renal angiography and RSDN in patients with moderate to severe CKD (eGFR 15–44 mL/min/1.73m²) and uncontrolled hypertension.

Results: Eleven patients (eight males) underwent RSDN. The median age was 57 years [interquartile range (IQR) 49–66]. The median number of antihypertensives being taken at baseline was 4 (IQR 3–4). No statistically significant difference was observed in serum creatinine in the serial follow-ups until at 6 months [median difference 0.25 mg/dL (IQR 0.09–0.53); P = 0.008]. There was a non-significant reduction in median clinic BP from baseline to 6 months [−14 mmHg (IQR −24–5)] and a significant increase in daytime ambulatory systolic BP [7 mmHg (IQR 2–12); P = 0.045]. A trend towards a serial reduction in albuminuria was observed. Procedure-related complications included a groin haematoma (n = 1) and reported flank pain (n = 1) and groin pain (n = 1).

Conclusions: This pilot study shows that CO₂ renal angiography can be used to perform RSDN in patients with significant renal impairment and may lead to associated improvements in clinic BP and albuminuria.

Key words: carbon dioxide angiography, chronic kidney disease (CKD), contrast nephropathy, renal sympathetic denervation, uncontrolled hypertension

Received: March 27, 2017. Editorial decision: May 31, 2017
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
Renal denervation in chronic kidney disease

Background
Hypertension is a risk factor for cardiovascular disease and chronic kidney disease (CKD). If it remains uncontrolled it can lead to rapid progression of CKD and is a leading cause of end-stage renal disease (ESRD). The latter is considered the most important. Symmetric renal involvement is important for the uncontrolled progression of the RAS because if a single kidney is affected, the other one compensates [5]. CKD is the perfect example of symmetric involvement. The sympathetic nervous system is also overactive and has been implicated to play role in the progression of CKD [6]. In ESRD, sympathetic nerve activity is substantially increased and elevated noradrenaline plasma levels have been linked with poor cardiovascular outcomes [7, 8]. Recently, procedure-based approaches have been investigated in patients with TRH to achieve BP control. Percutaneous catheter-based radiofrequency ablation of afferent and efferent sympathetic nerves of renal arteries is one such technique and is the most widely researched to date. It is purported to address certain interorgan crosstalk pathways that may be upregulated in non-atherosclerotic nephrogenic hypertension [9]. Due to the risk of contrast-induced nephropathy associated with the use of iodinated contrast materials, patients with significant renal impairment and has been successfully used in such patients for various diagnostic and therapeutic indications [10–14].

Carbon dioxide (CO2) angiography is a well-recognized and safe alternative to iodine-based contrast material in patients with CKD or iodinated contrast agent allergy [15–17]. A negative contrast image with digital subtraction angiography is produced when the directly injected CO2 displaces blood intravascularly. CO2 angiography has been shown to prevent deterioration of renal function in patients with known renal impairment and has been successfully used in such patients for various diagnostic and therapeutic indications [10, 16–18].

In this pilot study, we examined the safety and efficacy of RSDN performed using CO2 as the sole contrast agent in patients with significant renal impairment (eGFR 15–44 mL/min/1.73 m3).

Materials and methods
All patients 18–75 years of age were recruited from screening patients attending the outpatient nephrology and specialist hypertension clinic at Heart of England NHS Foundation Trust in Birmingham. Patients were screened based on their outpatient clinic systolic BP, number of antihypertensive medications used and outpatient eGFR. Only patients with TRH, outpatient clinic systolic BP >140 mmHg while taking at least three antihypertensive medications and an eGFR between 15 and 44 mL/min/1.73 m2 were selected for RSDN. Patients with an eGFR >45 mL/min/1.73 m2 or <15 mL/min/1.73 m2, diagnosis of type 1 diabetes mellitus, substantial stenotic valvular heart disease, pregnancy or planned pregnancy during the study and a history of myocardial infarction, unstable angina or cerebrovascular accident in the previous 6 months were excluded.

At the baseline visit, clinic BP was assessed in a standardized manner following the British Hypertension Society guidelines. Briefly, an average of at least two systolic BPs was used to confirm systolic hypertension. BP was taken with patients resting in a chair for 5 min and a 1-min interval between the end of one measurement and the start of the next measurement. All patients had baseline serum electrolytes, urea and creatinine, urinary albumin:creatinine ratio (ACR) and 24-h ambulatory BP measured. Serum creatinine was used to calculate eGFR using the Modification of Diet in Renal Disease (MDRD) equation to confirm that the baseline eGFR met the inclusion criteria. Anatomical suitability for RSDN was confirmed using non-contrast computed tomography (CT) reconstruction of renal arteries. Baseline data recorded include basic demographics, comorbidities and the number and names of antihypertensive medications.

Renal angiography was performed utilizing CO2 as the sole contrast agent to confirm the renal anatomy prior to performing RSDN [19]. The procedure was carried out in all patients by two interventional radiologists, both with considerable experience in both CO2 angiography and RSDN. RSDN was performed using either the single or multi-electrode radiofrequency Symplicity catheter (Medtronic, Mountain View, CA, USA) in all patients as described previously [20]. The procedure was carried out as a day case.

All patients were followed up at 7 days and 1, 3 and 6 months post-procedure to assess renal function and BP response and to monitor any potential procedural complications. At each visit a medication review, clinic BP and urinary ACR was carried out. At the baseline visit, clinic BP was assessed in a standardized manner following the British Hypertension Society guidelines. The Shapiro–Wilk test was applied to test for normality of distribution of data. Median and interquartile range (IQR) have been used to report the non-normally distributed parameters. Related-samples Wilcoxon signed rank test was used to compare baseline creatinine, eGFR and clinic and ABPM readings with follow-up readings to detect any statistically significant changes. A two-sided P-value <.05 was considered statistically significant. Written informed consent was obtained from all patients. The study was reviewed by the local research ethics committee (NRES Committee West Midlands, Edgbaston) and granted approval. The study was registered with ClinicalTrials.gov (NCT02863510).

Results
Eleven patients with CKD underwent RSDN. The baseline characteristics for the patients are summarized in Table 1. There were eight (72.7%) men and the median age was 57 years (IQR
The mean total number of radiofrequency ablations delivered during the RSDN procedure was 11.3 (SD 2.4). There were no minor atherosclerotic findings, which could have limited the radiofrequency ablation probe contact with the true wall of the artery, in any of the patients who underwent RSDN. Patients with significant renal artery stenosis due to any atherosclerotic lesions were excluded at the screening stage by CT renal angiogram. Procedure-related complications observed included one patient with flank pain that was managed with simple analgesics, another patient with groin pain that did not require any analgesics and another patient with a groin haematoma requiring overnight admission but no intervention. Two patients progressed to end-stage renal disease requiring dialysis; one patient commenced on peritoneal dialysis at 6 months and 10 days after the procedure and the other required haemodialysis at 5 months and 27 days.

Discussion

This is the first reported study to perform RSDN with the sole use of CO₂ as a contrast agent. This pilot study shows that CO₂ renal angiography can be used safely to perform RSDN in patients with significant renal impairment where there is a risk of contrast-induced nephropathy commonly associated with iodinated contrast agents. We showed that at 7 days after the procedure there was no significant change in the median serum creatinine and eGFR. There was no significant improvement in BP control, but there was a trend towards an improvement in albuminuria at 6 months.

The primary aim of this study was whether the use of iodinated contrast agents could be avoided in patients with significant renal impairment and uncontrolled hypertension to successfully perform RSDN using CO₂ angiography. CO₂ angiography is not completely risk free; however, the adverse events associated with CO₂ angiography are uncommon and are usually limited to the organs being injected [21]. In particular, a vapour lock phenomena can occur where the large doses of CO₂ can cause obstruction to blood flow and hence ischaemia downstream if unresolved. Contamination of CO₂ with room air can result in air embolus. Neurotoxicity, pain, nausea, vomiting and an urge to defecate are among the other possible complications. The risk of these rare complications can be reduced through understanding the unique properties of CO₂ and making sure appropriate precautions are observed when preparing and administering it [21, 22]. No patients in this study cohort suffered any adverse events that could be attributable to CO₂ angiography and the only observed adverse events were secondary to puncture site complications, which are common to any percutaneous angiographic procedure. CO₂ with digital subtraction angiography allowed adequate placement of the RSDN catheter to allow radiofrequency ablation, which was confirmed by the impedance drops observed for each ablation.

It is well known that the risk of developing contrast-induced nephropathy is associated with the volume of contrast used. CO₂ renal artery angiography has been used to reduce but not completely eliminate the amount of iodinated contrast given when carrying out intravascular procedures in individuals with significant renal function impairment [10]. In our study, the use of iodinated contrast agents has been wholly replaced by CO₂, completely negating the risk of developing contrast-induced nephropathy. There are no reported studies comparing the safety of CO₂ versus radio-iodine contrast with pre-procedural hydration in patients undergoing RSDN. However, a recent

---

Table 1. Baseline characteristics

| Characteristics                      | Results                  |
|--------------------------------------|--------------------------|
| Age (years), median (IQR)            | 57.0 (49.0–66.0)         |
| Gender, n (%)                        |                          |
| Male                                 | 8 (72.7)                 |
| Female                               | 3 (27.3)                 |
| Ethnicity, n (%)                     |                          |
| Caucasian                            | 7 (63.6)                 |
| Afro-Caribbean                       | 2 (18.2)                 |
| Asian                                | 2 (18.2)                 |
| BMI (kg/m²), median (IQR)            | 32.8 (25.7–38.7)         |
| Comorbidities, n (%)                 |                          |
| Type 2 diabetes mellitus             | 5 (45.5)                 |
| Cerebrovascular disease              | 2 (18.2)                 |
| Antihypertensive medication, n (%)   |                          |
| ACE inhibitor                        | 4 (36.4)                 |
| Angiotensin receptor blocker         | 5 (45.5)                 |
| Aldosterone antagonist               | 1 (9.1)                  |
| β-adrenergic blocker                 | 5 (45.5)                 |
| Calcium channel blocker              | 11 (100)                 |
| Loop diuretic                        | 5 (45.5)                 |
| Thiazide/thiazide-like diuretic      | 2 (18.2)                 |

49–66). Seven (63.6%) patients were Caucasian, two (18.2%) African Caribbean and two (18.2%) South Asian. The median number of antihypertensive medications taken by the study population at baseline was 4 (IQR 3–4). All patients were taking a calcium channel blocker (CCB), nine (81.8%) were taking either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker and seven (63.6%) were taking at least one diuretic (loop, thiazide/thiazide-like or potassium-sparing). At 6 months, most patients [n = 9 (81.8%)] were taking the same number of antihypertensive medications and two patients had at least one antihypertensive medication stopped.

Table 2 summarizes the results of renal function, albuminuria and BP parameters at the baseline and follow-up visits. The baseline median serum creatinine was 2.26 mg/dL (IQR 1.66–3.47) with a median eGFR of 29 mL/min/1.73 m² (IQR 18–41). The median of differences between serum creatinine at baseline and 6 months post-RSDN was 0.25 mg/dL (IQR 0.09–0.53), which was statistically significant (P = 0.008). The median of differences between serum creatinine at baseline and the earlier follow-up visits were not statistically significant. Similarly, the median of differences between eGFR at baseline and 6 months follow-up visit was statistically significant with a median difference of −4 mL/min/1.73 m² (IQR −11 to −1); P = 0.012. The median albuminuria, measured as urine ACR, of the study population showed an improving trend (Table 2); however, the median of differences in ACR at the baseline and follow-up visits was not statistically significant.

At baseline the median clinic BP was 170 mmHg (IQR 158–180) systolic and 89 mmHg (IQR 74–99) diastolic. The median clinic systolic BP was lower at 6 months but the median of the difference, −14 mmHg (IQR −24–5), was not statistically significant. The apparent reduction in the median clinic BP was not accompanied by a corresponding reduction in ambulatory BP parameters, where the median systolic BP was higher at 6 months overall and when separated into day and night (Table 2). Statistically, however, the median of the difference was only found to be significant for daytime systolic BP, which was 7 mmHg (IQR −2–12), P = 0.045. The change in all other ambulatory BPs was not statistically significant.
Renal denervation in chronic kidney disease

Table 2. Study parameters at baseline and serial follow-up

| Parameter                      | Baseline (n = 11) | Week 1 (n = 11) | Week 4 (n = 11) | Week 12 (n = 10) | Week 26 (n = 11) |
|-------------------------------|------------------|----------------|----------------|------------------|------------------|
| Creatinine (mg/dL)            | 2.26 (1.66–3.47) | 2.02 (1.91–3.45) | 2.27 (1.75–3.35) | 2.21 (1.75–4.07) | 2.24 (1.71–3.81) |
| eGFR (mL/min/1.73 m²)         | 29 (18–41)       | 33 (19–36)     | 29 (20–38)     | 28 (16–38)       | 25 (17–34)       |
| Urine ACR (mg/mmol)           | 203 (63–412)     | 231 (55–283)   | 136 (23–386)   | 146 (15–382)     | 137 (6–370)      |
| Clinic SBP (mmHg)             | 170 (158–180)    | 169 (158–175)  | 157 (135–170)  | 159 (152–177)    | 164 (149–174)    |
| Clinic DBP (mmHg)             | 89 (75–95)       | 87 (78–87)     | 83 (74–91)     | 86 (71–103)      | 86 (74–94)       |
| 24-h ambulatory SBP (mmHg)    | 155 (149–161)    | 86 (73–94)     | 89 (75–95)     | 155 (144–169)    | 83 (74–90)       |
| 24-h ambulatory DBP (mmHg)    | 159 (149–164)    | 86 (73–94)     | 89 (75–95)     | 155 (144–169)    | 83 (74–90)       |
| Day ambulatory SBP (mmHg)     | 159 (149–164)    | 86 (73–94)     | 89 (75–95)     | 155 (144–169)    | 83 (74–90)       |
| Day ambulatory DBP (mmHg)     | 159 (149–164)    | 86 (73–94)     | 89 (75–95)     | 155 (144–169)    | 83 (74–90)       |
| Night ambulatory SBP (mmHg)   | 147 (141–163)    | 86 (71–103)    | 89 (75–95)     | 155 (144–169)    | 83 (74–90)       |
| Night ambulatory DBP (mmHg)   | 147 (141–163)    | 86 (71–103)    | 89 (75–95)     | 155 (144–169)    | 83 (74–90)       |

All values are given as median (IQR). Conversion factor for creatinine in mg/dL to µmol/L × 88.4. DBP, diastolic blood pressure; SBP, systolic blood pressure.

meta-analysis comparing the incidence of acute kidney injury with CO₂ versus iodinated contrast media reported that CO₂ use is associated with a modestly reduced rate of AKI despite the patients with iodinated contrast media being optimized with pre-hydration [23]. Furthermore, a recent randomized controlled trial of prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy found no prophylaxis to be non-inferior and cost saving in preventing contrast-induced nephropathy compared with intravenous hydration [24]. Patients with CKD are at a higher risk of developing contrast nephropathy and any measures that help reduce the risk of contrast-induced nephropathy should be considered for patients undergoing interventional procedures.

Unlike other studies of RSDN [25, 26], only a modest reduction in clinic systolic BP was observed 6 months after RSDN. Conversely, ambulatory systolic BP readings were higher at 6 months. The most likely explanation for this observed rise in ambulatory systolic BP could be progression of CKD and the consequent sodium and water retention. In nine (82%) of the patients serum creatinine was higher, and accordingly a lower eGFR, at 6 months after RSDN when compared with baseline values.

The median serum creatinine at 7 days after RSDN showed no significant decline and, if anything, a trend towards improved creatinine. However, by 6 months the decline in kidney function was statistically significant, suggesting a continued progression of CKD. Given the small number of patients in the study, a detailed analysis of whether RSDN affected the rate of decline in kidney function was not performed. A recent study in 46 patients with CKD (baseline eGFR ≤ 60 mL/min/1.73 m²) has provided some evidence that RSDN can slow further deterioration of renal function irrespective of BP-lowering effects [14]. These results build on similar findings reported by others [13, 27].

There is some evidence to suggest that RSDN may have a beneficial effect in reducing urinary albumin excretion that may be unrelated to improvement in BP control [27]. In this study, a non-significant trend towards improved urinary excretion appeared at 4 weeks post-procedure and was maintained at subsequent follow-ups until 6 months.

Conclusions

This is the first study of RSDN in patients with moderate to severe CKD that has avoided the use of traditional iodinated contrast media altogether by replacing it with CO₂ angiography. However, this was a pilot single-arm study with no sham comparator and was not powered to detect a meaningful reduction in clinic or ambulatory BPs. The results have shown that there were no adverse procedural events associated with CO₂ angiography and any future trials of RSDN should not exclude patients with moderate to severe CKD on the basis of the risk of contrast-induced nephropathy associated with the conventional methods. Further research, with a larger study population, is needed to investigate whether RSDN can achieve substantial reductions in BP and albuminuria and have any effect on the rate of decline of CKD.

Funding

This work has been supported by an unrestricted research grant from Medtronic (to J.S.F. and I.D.) and unrestricted educational grants from Medtronic and Biosensors (to R.W.).

Conflict of interest statement

None declared.

References

1. Muntner P, Anderson A, Charleston J et al. Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis 2010; 55: 441–451
2. Mahmoodi BK, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380: 1649–1661
3. Sag AA, Covic A, London G et al. Clinical imaging of vascular disease in chronic kidney disease. Int Urol Nephrol 2016; 48: 827–837
4. Bakris GL, Williams M, Dworin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–661
5. Sag AA, Kos T, Benli C et al. Atherosclerotic renal artery stenosis in the post-CORAL era part 2: new directions in transcatheter nephron salvage following flawed revascularization trials. J Am Soc Hypertens 2016; 10: 368–377
6. Grassi G, Quarti-Trevano F, Seravalle G et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011; 57: 846–851
7. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354–1359

8. Schlaich MP, Socratous F, Hennebry S et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20: 933–939

9. Sag A, Sal O, Kilic Y et al. The concept of crosstalk-directed embryological target mining and its application to essential hypertension treatment failures. J Clin Hypertens 2017; 19: 530–533

10. Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23: 1250–1257

11. Kiuchi MG, Maia GL, de Queiroz Carreira MA et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J 2013; 34: 2114–2121

12. Kiuchi MG, Chen S, Andrea BR et al. Renal sympathetic denervation in patients with hypertension and chronic kidney disease: does improvement in renal function follow blood pressure control? J Clin Hypertens 2014; 16: 794–800

13. Ott C, Mahfoud F, Schmid A et al. The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. J Hypertens 2016; 34: 2475–2479

14. Hering D, Marusic P, Duval J et al. Effect of renal denervation on kidney function in patients with chronic kidney disease. Int J Cardiol 2017; 232: 93–97

15. Moos JM, Ham SW, Han SM et al. Safety of carbon dioxide digital subtraction angiography. Arch Surg 2011; 146: 1428–1432

16. Kawasaki D, Fuji K, Fukunaga M et al. Safety and efficacy of carbon dioxide and intravascular ultrasound-guided stenting for renal artery stenosis in patients with chronic renal insufficiency. Angiology 2015; 66: 231–236

17. Fujihara M, Kawasaki D, Shintani Y et al. Endovascular therapy by CO₂ angiography to prevent contrast-induced nephropathy in patients with chronic kidney disease: a prospective multicenter trial of CO₂ angiography registry. Catheter Cardiovasc Interv 2015; 85: 870–877

18. Schreier DZ, Weaver FA, Frankhouse J et al. A prospective study of carbon dioxide—digital subtraction vs standard contrast arteriography in the evaluation of the renal arteries. Arch Surg 1996, 131: 503–508

19. Renton M, Hameed MA, Dasgupta I et al. The use of carbon dioxide angiography for renal sympathetic denervation: a technical report. Br J Radiol 2016; 89: 20160311

20. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275–1281

21. Caridi JG, Hawkins IF Jr. CO₂ digital subtraction angiography: potential complications and their prevention. J Vasc Interv Radiol 1997; 8: 383–391

22. Hawkins IF, Caridi JG. Carbon dioxide (CO₂) digital subtraction angiography: 26-year experience at the University of Florida. Eur Radiol 1998; 8: 391–402

23. Ghumman SS, Weinerman J, Khan A et al. Contrast induced-acute kidney injury following peripheral angiography with carbon dioxide versus iodinated contrast media: a meta-analysis and systematic review of current literature. Catheter Cardio Inte 2017. doi:10.1002/ccd.27051

24. Nijssen EC, Rennenberg RJ, Nelemans PJ et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017; 389: 1312–1322

25. Bhatt DL, Kandzari DE, O’Neill WW et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393–1401

26. Azizi M, Sapoval M, Gosse P et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385: 1957–1965

27. Kiuchi MG, Graciano ML, Carreira MA et al. Long-term effects of renal sympathetic denervation on hypertensive patients with mild to moderate chronic kidney disease. J Clin Hypertens 2016; 18: 190–196